While ER-positive breast cancers typically result in better clinical outcomes23, among the luminal breast cancers, DSCAM-AS1 is expressed significantly higher in luminal B, a clinical subtype containing most of the clinically aggressive ER-positive breast cancers22, 23 (Fig. 3c). The gene discussed is DSCAM-AS1; the disease is breast cancer.